StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Pharmaceutical Segment — Worldwide sales by Quarter

Pharmaceutical Segment — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Pharmaceutical Segment — Worldwide sales: $14,760M in Q2 2026, up 5.1% from a year earlier.

Latest, Q2 2026
14,760
Period ended Jun 30, 2026
Change on a year earlier
+5.1%
14,050 in Q2 2025
History
42 quarters
Since Q1 2016
Sources
10
Documents cited below

Where the Q2 2026 figure comes from

“|| PHARMACEUTICAL | 14,760 | 14,050 | 5 | 8,827 | 8,328 | 6 | 5,933 | 5,722 | 4”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b / 3c & Form 10-Q / 10-K Segment Footnote.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Segment — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202614,760+5.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 202614,349+5.2%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202514,843+5.7%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 202515,611+4.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 202514,050-2.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 202513,638-2.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 202414,042+6.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202414,943+4.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202414,408+7.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202414,006+10.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202313,141+7.9%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202314,263+10.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202313,457+5.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202312,721-9.8%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202212,180+1.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202212,963+12.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up pharmaceutical Segment — Worldwide sales

Cite this data

StockData. (2026). Merck Pharmaceutical Segment — Worldwide sales ($M), quarterly Q1 2016–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-pharma-seg

See every metric in the Merck KPI table. Data updated Oct 26, 2026.